Table I.
Demographic and clinical characteristics of the patients with breast cancer in the present study.
| Characteristic | Value |
|---|---|
| Total patients, n | 97 |
| Agea, years | |
| Median (95% CI) | 55 (52-57) |
| <50, n (%) | 25(26) |
| ≥50, n (%) | 72(74) |
| Menopausal statusa, n (%) | |
| Perimenopausal | 30(31) |
| Postmenopausal | 67(69) |
| Comorbiditya, n (%) | |
| Hypertension | 14(14) |
| Diabetes | 14(14) |
| Cardiovascular disease | 9(9) |
| Others | 64(66) |
| Stage at initial diagnosis, n (%) | |
| Early/locally advanced | 53(55) |
| Metastatic | 44(45) |
| Hormone receptor status, n (%) | |
| ER-positive | 97(100) |
| PR-positive | 84(87) |
| Adjuvant ET, n (%) | 53(55) |
| Disease-free interval for early diseaseb, n (%) | |
| <12 months | 32(33) |
| 12-24 months | 2(2) |
| >24 months | 19(20) |
| Prior chemotherapya, n (%) | |
| None | 9(9) |
| Neo/adjuvant | 20(21) |
| For metastatic disease | 53(55) |
| Neo/adjuvant/metastatic | 15(15) |
| ET lines for metastatic diseasea, n (%) | |
| One | 49(51) |
| Two | 31(32) |
| Three or more | 17(18) |
| Prior ET sensitivitya, n (%) | |
| Yes | 9(9) |
| No | 77(79) |
| Unknown | 11(11) |
| Metastatic sitesa, n (%) | |
| Bone only | 26(27) |
| Bone | 84(87) |
| Lung/pleura | 42(43) |
| Liver | 56(58) |
| Brain | 18(19) |
| Number of metastatic sitesa, n (%) | |
| One | 33(34) |
| Two | 35(36) |
| Three or more | 29(30) |
| Response to therapya, n (%) | |
| Complete response | 4(4) |
| Partial response | 25(26) |
| Stable disease | 21(22) |
| Progression | 36(37) |
| Not assessable | 11(11) |
aAt palbociclib initiation.
b(n=53). CI, confidence interval; ET, endocrine therapy; ER, estrogen receptor; PR, progesterone receptor.